Latest argenx News & Updates

See the latest news and media coverage for argenx. We track all announcements, press releases, and industry mentions in real time, all in one place.

argenx

Immunology-focused biopharmaceutical company

argenx.com

Headquarters: Boston, United States
Founded year: 2008
Company type: Public company
Number of employees: 2,200–5,000
Industry: Pharmaceuticals

Last updated Today

Latest news about argenx

In short: Argenx grew annual product sales to $4.2 billion and achieved its first year of profitability while appointing Karen Massey as its new CEO.

Company announcements

July 27 argenx

argenx acquires Forte Biosciences for $2.2 billion

The deal adds first-in-class anti-CD122 antibody FB102 to its immunology pipeline targeting autoimmune diseases.

July 23 argenx

argenx reports half year 2026 financial results and business update

Second quarter product net sales reached $1.5 billion, a 60% year-over-year increase, and the company expanded VYVGART label to all gMG serotypes.

May 22 argenx

argenx announces FDA approval for seronegative gMG treatment

The treatment targets a historically underserved community with a rare form of myasthenia gravis.

May 8 argenx

argenx announces FDA expands VYVGART label

Approval extends indication to all adult gMG serotypes based on Phase 3 ADAPT SERON data.

Media coverage

July 30 Yahoo Finance

The Charts Reveal Significant Price Movement in Forte Biosciences Stock Ahead of Argenx’s Acquisition Announcement

Argenx (ARGX) announced the acquisition of Forte Biosciences (FBRX) at $77 per share on July 27....

July 26 Reuters

Argenx to buy Forte Biosciences for about $2.2 billion

Belgian-Dutch immunology company argenx will buy ‌Forte Biosciences to add experimental autoimmune...

July 24 ZoneBourse

Argenx continues its rise, DZ Bank raises its target

Yesterday, the immunology specialist company unveiled its quarterly results and its share ended the session up 5.09%. Today, DZ...

July 23 Morningstar

Argenx's Robust Vyvgart Growth Drives Margin Expansion as Pipeline Advances

Morningstar is an investment research company offering mutual fund, ETF, and stock analysis, ratings, and data, and portfolio tools. Discover actionable insights today.

Never miss news about argenx

Track argenx and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

argenx competitors & trending companies

Browse news for competitors to argenx and other trending companies.